{
    "nctId": "NCT01332981",
    "briefTitle": "An Observational Follow-up Study of 1st-Line Treatment With Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer (Post-HERMINE)",
    "officialTitle": "Overall Survival Estimation After a 7 Year Follow-up in Metastatic Breast Cancer Patients Treated by Herceptin\u00ae as 1st Line Therapy (Post-HERMINE Study)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 220,
    "primaryOutcomeMeasure": "Median Overall Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patient, \\>/= 18 years of age\n* Metastatic breast cancer\n* 1st-line treatment with Herceptin initiated in 2002\n* Included in pharmaco-epidemiologic HERMINE study\n\nExclusion Criteria:\n\n* Patient died before scheduled follow-up visit (March 2005)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}